Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials

Chu, Derek K.; Chu, Alexandro W.L.; Rayner, Daniel G.; Guyatt, Gordon H.; Yepes-Nuñez, Juan José; Gomez-Escobar, Luis; Pérez-Herrera, Lucia C.; Díaz Martinez, Juan Pablo; Brignardello-Petersen, Romina; Sadeghirad, Behnam; Wong, Melanie M.; Ceccacci, Renata; Zhao, Irene X.; Basmaji, John; MacDonald, Margaret; Chu, Xiajing; Islam, Nazmul; Gao, Ya; Izcovich, Ariel; Asiniwasis, Rachel N.; Boguniewicz, Mark; De Benedetto, Anna; Capozza, Korey; Chen, Lina; Ellison, Kathy; Frazier, Winfred T.; Greenhawt, Matthew; Huynh, Joey; LeBovidge, Jennifer; Lio, Peter A.; Martin, Stephen A.; O’Brien, Monica; Ong, Peck Y.; Silverberg, Jonathan I.; Spergel, Jonathan M.; Smith Begolka, Wendy; Wang, Julie; Wheeler, Kathryn E.; Gardner, Donna D.; Schneider, Lynda

doi:10.1016/j.jaci.2023.08.030

Cited by 16 publications

(7 citation statements)

References 201 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The AD therapeutic paradigm has undergone very important changes over the last few years. [3][4][5][6][7]29 In addition, treatment of AD should follow a multifaceted, stepwise approach that is tailored according to disease severity. [3][4][5][6][7]29,30 Since AD has a complex and incompletely understood pathophysiology, as well as a heterogeneous course, not all patients will respond equally to all therapies.…”

Section: Discussionmentioning

confidence: 99%

“…phenotype subtype, ethnicity and any history of conjunctivitis). [3][4][5][6][7] Systemic treatment for AD has experienced a significant development in recent years.…”

Section: Introductionmentioning

confidence: 99%

“…2 There are different therapeutic options for treating AD, including skin care, assessment and elimination of exacerbating factors and drug therapy. [3][4][5][6][7] To select the optimal treatment strategy, it is necessary to perform a thorough and accurate assessment of disease severity and identification of potential biomarkers (i.e. phenotype subtype, ethnicity and any history of conjunctivitis).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of potential predictive factors of dupilumab response in patients with moderate‐to‐severe atopic dermatitis

Melé‐Ninot,

Curto‐Barredo,

Bonfill‐Ortí

et al. 2023

Aust J Dermatology

View full text Add to dashboard Cite

BackgroundDupilumab has shown to be an effective and safe treatment for patients with moderate‐to‐severe atopic dermatitis (AD).ObjectiveTo evaluate the predictive factors of response (PRF) in patients with moderate‐to‐severe AD treated with dupilumab.MethodsObservational, retrospective and multicentre study conducted on adult patients diagnosed with moderate‐to‐severe AD treated with dupilumab, with a post‐treatment follow‐up of at least 16 weeks. The primary endpoints were EASI‐75 and the IGA scale at week 52.ResultsA total of 198 patients were included in the analysis. Mean age was 38 ± 15.1 years and 116 (58.6%) were men. The most prevalent AD‐predominant phenotypes were flexural eczema (45.3%), head‐and‐neck eczema (18.2%) and erythroderma (17.7%). At week 52, 140 (86.4%) patients achieved EASI‐75 and 119 (93.0%) achieved an improvement in ≥2 points from baseline in IGA score. Women were 3.6 times more likely to achieve EASI‐75 response than men (Odds ratio: 3.58; p = 0.020). While increased body mass index significantly reduced the probability of obtaining an improvement of ≥2 points in the IGA scale at week 52 (odds ratio: 0.88; p = 0.049).ConclusionsDupilumab was an effective treatment in patients with moderate‐to‐severe AD. Additionally, sex and body mass index were significantly associated with achieving EASI‐75 and an improvement of ≥2 points in the IGA scale, respectively, at week 52.

show abstract

Section: Discussionmentioning

confidence: 99%

“…phenotype subtype, ethnicity and any history of conjunctivitis). [3][4][5][6][7] Systemic treatment for AD has experienced a significant development in recent years.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of potential predictive factors of dupilumab response in patients with moderate‐to‐severe atopic dermatitis

Melé‐Ninot,

Curto‐Barredo,

Bonfill‐Ortí

et al. 2023

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

“…Наиболее частыми причинами обращений к дерматологу родителей с детьми первых двух лет жизни являются атопический дерматит и аллергический контактный дерматит [4,5].…”

Section: распространенность воспалительных заболеваний кожи у детей п...unclassified

Peculiarities of treatment of dermatitis in young children

Sharova,

Kukalo

2024

Medicinskij sovet

View full text Add to dashboard Cite

The skin of children of the first years of life has a number of structural and physiological features that determine the development of inflammatory process and clinical picture of the disease. Inflammatory skin diseases such as atopic dermatitis and allergic contact dermatitis are common in children in the first two years of life. Atopic dermatitis (AD) develops in individuals with hereditary predisposition, has a chronic recurrent course, is characterized by itching, typical morphology and localization of lesions. The prevalence of atopic dermatitis is up to 20%. Contact allergic dermatitis develops on the background of monovalent sensitization, the prevalence is about 16.5%. The clinical picture depends on the severity of the inflammatory reaction and the duration of the disease. The main goal of treatment of allergodermatoses is to stop the signs of inflammation, subjective symptoms. External therapy of inflammatory skin diseases consists in the prescription of topical glucocorticosteroids. When choosing the means of external therapy, it is necessary to take into account the age of the patient, the degree of severity of the inflammatory process, localization of lesions, pharmacokinetics of the active substance and other factors. The article describes clinical cases of treatment of atopic dermatitis, contact allergic dermatitis in patients of the first two years of life using methylprednisolone aceponate with ceramides in the form of cream, ointment. High efficacy and safety of topical corticosteroids in infants in combination with emollients has been shown to rapidly reduce the intensity of inflammation and subjective symptoms.

show abstract

“…The primary approach for managing AD involves the use of topical corticosteroids as the first-line treatment [3]. As per a recent comprehensive review and meta-analysis, the treatments found to be most effective for AD comprise pimecrolimus, tacrolimus, and topical corticosteroids with moderate potency [4]. While high-potency topical corticosteroids are more effective, they come with an increased risk of local and, rarely, systemic adverse effects.…”

Section: Introductionmentioning

confidence: 99%

New Topical Treatment for Atopic Dermatitis

Calvo,

Cobo,

Allam

2024

EJMED

View full text Add to dashboard Cite

The primary approach for managing atopic dermatitis (AD) involves the use of topical corticosteroids as the first-line treatment.While high-potency topical corticosteroids have shown to be effective, they come with an increased risk of local and, rarely, systemic adverse effects. Additionally, patients often experience a relapsing and remitting course. A revolutionary topical treatment for psoriasis and AD has recently received patent approval from the Spanish Ministry of Industry, Trade, and Tourism. This innovative treatment, presented in the form of a lotion, includes a combination of clobetasol, papaverine hydrochloride, spironolactone, a milk-peptide complex, and propylene glycol. An 18-year-old female presented with AD on the back of her neck and scalp. The patient had no significant past medical history and primarily complained of intense pruritus in the AD lesions. The patient received guidance to apply our recently patented lotion, Psorisbye, once a day for 5 days. In total, 50 ml of Psorisbye was utilized over 4 days. On the fifth day, the patient underwent an examination at the outpatient clinic. The patient reported a significant improvement in pruritus sensations and observed a reduction in scaled lesions. Upon evaluating our patient, a comparison of the lesions before and after applying the topical treatment for 4 days revealed a notable improvement in the SCORAD index, decreasing from 49.95 to 0. While the results of Psorisbye in this case show promise, it is crucial to conduct further studies with larger sample sizes and extended follow-up periods to validate the findings presented in our case report.

show abstract

Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials

Cited by 16 publications

References 201 publications

Assessment of potential predictive factors of dupilumab response in patients with moderate‐to‐severe atopic dermatitis

Assessment of potential predictive factors of dupilumab response in patients with moderate‐to‐severe atopic dermatitis

Peculiarities of treatment of dermatitis in young children

New Topical Treatment for Atopic Dermatitis

Contact Info

Product

Resources

About